<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938352</url>
  </required_header>
  <id_info>
    <org_study_id>CR8020FLZ2002</org_study_id>
    <secondary_id>CRU-CS-001</secondary_id>
    <nct_id>NCT01938352</nct_id>
  </id_info>
  <brief_title>Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge</brief_title>
  <official_title>Randomised, Double-Blind, Placebo-Controlled, Phase IIa Study in Healthy Volunteers to Evaluate the Protective Efficacy and Safety of CR8020 in an Influenza Challenge Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Retroscreen Virology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Crucell Holland BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After prophylactic vaccination with CR8020, a monoclonal antibody, subjects will be
      challenged with the H3N2 virus. The protective efficacy, safety, tolerability,
      pharmacokinetics, and potential immunogenicity will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of viral load</measure>
    <time_frame>Day 7</time_frame>
    <description>Measured from the nasopharyngeal mucosa (by qPCR) post influenza virus challenge</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>CR8020</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CR8020 administered as a single 2-hour intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as a single 2-hour intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CR8020</intervention_name>
    <description>CR8020 15 mg/kg, administered by intravenous infusion</description>
    <arm_group_label>CR8020</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (hydrous dextrose in water for injection), administered by intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects ≥ 18 and ≤ 45 years of age.

          2. In good health, with no major medical conditions from medical history, physical
             examination, and routine laboratory tests as determined by the Investigator at a
             screening evaluation.

          3. A total body weight ≥50 kg and a BMI of &gt;18. If the BMI is above 28 the subject may be
             included if the waist measurement is less than 94 cm (male), or less than 80 cm
             (female).

          4. (a) Male subjects must use highly effective contraception consisting of two forms of
             birth control (one of which must be a barrier method) starting at entry to Quarantine
             until after the Day 96 (± 5 days) Follow-up Visit.

             (b) In addition, male subjects must not donate sperm following discharge from
             Quarantine until after the Day 96 (± 5 days) Follow-up Visit.

             (c) Female subjects must be either:

               -  Documented status as surgically sterile or post hysterectomy or-

               -  If of childbearing potential, must have a negative serum and urine pregnancy test
                  at study specific screening and Day -4/-3 and must be using highly effective
                  contraception consisting of two forms of birth control (one of which must be a
                  barrier method) starting at entry to Quarantine and continue until the Day 96 (±
                  5 days) Follow-up Visit.

             Acceptable forms of effective contraception include:

               -  Established use of oral, injected or implanted hormonal methods of contraception

               -  Placement of an intrauterine device (IUD) or intrauterine system (IUS).

               -  Barrier methods of contraception: Condom or occlusive cap (diaphragm or
                  cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.

               -  Male sterilisation (with the appropriate post-vasectomy documentation of the
                  absence of sperm in the ejaculate). [For female subjects on the study, the
                  vasectomised male partner should be the sole partner for that subject].

             True abstinence: When this is in line with the preferred and usual lifestyle of the
             subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal,
             post-ovulation methods) and withdrawal are not acceptable methods of contraception].

          5. An informed consent document signed and dated by the subject and Investigator.

          6. Sero-suitable for challenge virus.

        Exclusion Criteria:

          1. Subjects who have a significant history of tobacco use at any time (≥ total 10 pack
             year history, e.g. one pack a day for 10 years)

          2. (a) Females who are pregnant or have been pregnant within six months prior to the
             study, or who have been breastfeeding within three months prior to screening. Females
             who have a positive pregnancy test at any point in the study will be withdrawn
             immediately.

             (b) Females intending to become pregnant within three months of administration of
             CR8020 or placebo or males with female partners intending to become pregnant within
             three months of administration of CR8020 or placebo

          3. Any history or evidence of any clinically significant cardiovascular,
             gastrointestinal, endocrinological, haematological, hepatic, immunological, metabolic,
             urological, neurological, psychiatric, renal, and/or other major disease or
             malignancy, as judged by the Investigator

               1. Eczema/Atopic Dermatitis: (Subjects with clinically mild eczema/atopic dermatitis
                  may be included at the Investigator's discretion e.g. if there is no regular use
                  of topical steroids, no eczema in cubital fossa)

               2. Psoriasis:(Subjects with active psoriasis affecting less than 5% of the body's
                  surface area for the past five years can be included at the Investigator's
                  discretion- (1% of the body area is roughly equivalent to the palm of the
                  subject's hand). Patients with a history of completely resolved guttate psoriasis
                  can be included)

               3. Psychiatric: (Subjects with a diagnosis of a single mild or moderate depressive
                  episode two or more years ago, with good evidence of preceding stressors and
                  which resolved within approximately three months (i.e. reactive depression), may
                  be included at the Investigator's discretion)

          4. Abnormal pulmonary function in the opinion of the Investigator as evidenced by
             clinically significant abnormalities on spirometry

          5. History or evidence of autoimmune disease or known immunodeficiency of any cause

          6. Subjects with any history of asthma, chronic obstructive pulmonary disease (COPD),
             pulmonary hypertension, reactive airway disease, or chronic lung condition of any
             aetiology (See No. 7 for asthma)

          7. Asthma (A history of childhood asthma before the age of 12 is acceptable provided the
             subject is asymptomatic without treatment. Patients with a single episode of wheezing
             after age 12 (lasting less than eight weeks) can be included at the Investigator's
             discretion)

          8. Positive human immunodeficiency virus (HIV), Hepatitis A (HAV), B (HBV), or C (HCV)
             test

          9. Any significant abnormality altering the anatomy of the nose or nasopharynx

         10. Any clinically significant history of epistaxis

         11. Any nasal or sinus surgery within six months of Viral Challenge

         12. Recurrent history of clinically significant autonomic dysfunction

         13. Any abnormal laboratory test or ECG which is deemed by the Investigator to be
             clinically significant

         14. Confirmed positive test for drugs of abuse deemed by the Investigator to be clinically
             significant

         15. Venous access deemed inadequate for the phlebotomy and cannulation demands of the
             study

         16. Known allergy to any of the following:

               -  excipients in the Challenge Virus inoculum

               -  any CR8020 excipients (sucrose, L-histidine L-histidine monohydrochloride,
                  polysorbate 20)

               -  oseltamivir or other influenza treatments

         17. Health care workers (e.g. doctors, nurses, medical students and allied healthcare
             professionals) who work in units with severely immuno-compromised patients (e.g. bone
             marrow transplant units)

         18. Presence of household member or close contact(s) (for an additional two weeks after
             discharge from the isolation facility) who:

               -  has known immunodeficiency

               -  is receiving immunosuppressant medication

               -  is undergoing or soon to undergo cancer chemotherapy within 28 days of Viral
                  Challenge

               -  has been diagnosed with emphysema, COPD, or other severe lung disease and resides
                  in a nursing home

               -  has received a bone marrow or solid organ transplant

         19. Evidence of vaccinations within the four weeks prior to Human Viral Challenge.
             Intention to receive travel vaccination(s) before the Day 96 (± 5 days) Follow Up
             Visit

         20. Those employed or immediate relatives of those employed at Retroscreen Virology
             Limited or the Sponsor

         21. Receipt of blood or blood products, or loss (including blood donations) of 450 mL or
             more of blood, during the three months prior to Viral Challenge or planned
             donation/receipt throughout the course of the study

         22. Use of nasal steroids within 28 days prior to Viral Challenge Use of any other
             medication or product (prescription or over-the-counter), for symptoms of hay fever,
             rhinitis, nasal congestion or respiratory tract infection within seven days of Viral
             Challenge

         23. Receipt of any investigational drug within three months prior to Viral Challenge Prior
             participation in a clinical trial with the same strain of respiratory virus
             Participation in any other Human Viral Challenge study with a respiratory virus within
             one year prior to the day of Viral Challenge

         24. Receipt of systemic glucocorticoids, antiviral drugs, or immunoglobulins (Igs) or any
             other cytotoxic or immunosuppressive drug within six months prior to dosing, or
             receipt or any systemic chemotherapeutic agent at any time

         25. Previous receipt of monoclonal antibodies or monoclonal antibody fragments at any time

         26. Presence of significant respiratory symptoms existing on the day of challenge or
             between admission to the unit and inoculation with the Challenge Virus History
             suggestive of respiratory infection within 14 days prior to admission to the
             Quarantine Unit

         27. Any other finding that, in the opinion of the Investigator or Sponsor, deems the
             subject unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Retroscreen Virology Ltd</name>
      <address>
        <city>London</city>
        <zip>E1 2AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Virus</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <keyword>Immunization</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

